Regeneron Pharma (REGN) Tops Q2 EPS by 17c; EYLEA Sales Rose 26%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Regeneron Pharma (REGN) Price Target Raised to $425 at Deutsche Bank
August 5, 2014 12:54 PM EDTDeutsche Bank reiterated a Buy rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $425.00 (from $410.00).
Analyst Robyn Karnauskas said, "Eylea 2Q sales in the US were $415M vs. $410M consensus. In 1Q14 the... More
Roth Capital Comments on Regeneron (REGN) Following Q2 Results; Affirms 'Buy' Rating
August 5, 2014 12:29 PM EDTRoth Capital affirms Regeneron Pharmaceuticals (Nasdaq: REGN) at Buy with a target price of $399 following Q2 results.
Analyst Joseph Pantginis commented, REGN 2Q14 results show a 45% year-to-year growth in revenue as well as a 26% Eylea net sales growth, demonstrating the effective market penetration of the product. Recall that Eylea is already approved in the U.S. and E.U. for wet AMD and macular edema... More
